Optimal Use of Fluoroquinolones in the Intensive Care Unit Setting

被引:12
作者
Rotschafer, John C. [1 ]
Ullman, Mary A. [2 ]
Sullivan, Christopher J. [3 ]
机构
[1] Univ Minnesota, Coll Pharm, Dept Expt & Clin Pharmacol, Minneapolis, MN 55455 USA
[2] Reg Hosp, Dept Clin Pharm, St Paul, MN USA
[3] Fairview Hosp Syst, Minneapolis, MN USA
关键词
Fluoroquinolone antibiotics; Intensive care unit; Pharmacodynamics; PSEUDOMONAS-AERUGINOSA; QUINOLONE RESISTANCE; DNA TOPOISOMERASES; RISK-FACTOR; PHARMACODYNAMICS; CIPROFLOXACIN; LEVOFLOXACIN; SPARFLOXACIN; PNEUMONIA; SELECTION;
D O I
10.1016/j.ccc.2010.11.005
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Fluoroquinolones have become a staple antimicrobial in a variety of settings for a wide spectrum of infectious diseases. Although fluoroquinolones have been associated with a broad spectrum of adverse events, the side effect profile is generally acceptable. Their use in the intensive care unit as empiric therapy is becoming compromised due to the development of multiple drug resistant gram negative pathogens and collateral damage with C difficile & MRSA. Fluoroquinolones should be used along with another antibiotic of different chemical structure, mechanism of action, and pharmacodynamic profile to ensure adequate initial antimicrobial coverage and maximize the likelihood of a favorable clinical and microbiologic response.
引用
收藏
页码:95 / +
页数:13
相关论文
共 37 条
  • [1] Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit
    AlvarezLerma, F
    Pellus, AM
    Sanchez, BA
    Ortiz, EP
    Jorda, R
    Barcenilla, F
    Maravi, E
    Galvan, B
    Palomar, M
    Serra, J
    Bermejo, B
    Mateu, A
    Quintana, E
    Palacios, MS
    Giral, R
    Gonzalez, V
    Lerma, FA
    Mesa, JL
    Melgarejo, JA
    Martinez, J
    Insausti, J
    Olaechea, P
    Chanovas, M
    Gilabert, A
    Junquera, C
    Valles, J
    Palacios, F
    Calvo, R
    Mesalles, E
    Nava, J
    Santos, A
    Armengol, S
    Marzo, D
    [J]. INTENSIVE CARE MEDICINE, 1996, 22 (05) : 387 - 394
  • [2] Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections
    Ambrose, PG
    Grasela, DM
    Grasela, TH
    Passarell, J
    Mayer, HB
    Pierce, PF
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) : 2793 - 2797
  • [3] DNA topoisomerases: Structure, function, and mechanism
    Champoux, JJ
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 2001, 70 : 369 - 413
  • [4] Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis
    Chan, ED
    Laurel, V
    Strand, MJ
    Chan, JF
    Huynh, MLN
    Goble, M
    Iseman, MD
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 169 (10) : 1103 - 1109
  • [5] DNA gyrase, topoisomerase IV, and the 4-quinolones
    Drlica, K
    Zhao, XL
    [J]. MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, 1997, 61 (03) : 377 - +
  • [6] Relationship between fluoroquinolone area under the curve:minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia
    Drusano, GL
    Preston, SL
    Fowler, C
    Corrado, M
    Weisinger, B
    Kahn, J
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (09) : 1590 - 1597
  • [7] Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia
    Dupont, H
    Mentec, H
    Sollet, JP
    Bleichner, G
    [J]. INTENSIVE CARE MEDICINE, 2001, 27 (02) : 355 - 362
  • [8] PHARMACODYNAMICS OF INTRAVENOUS CIPROFLOXACIN IN SERIOUSLY ILL-PATIENTS
    FORREST, A
    NIX, DE
    BALLOW, CH
    GOSS, TF
    BIRMINGHAM, MC
    SCHENTAG, JJ
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (05) : 1073 - 1081
  • [9] Mechanochemical analysis of DNA gyrase using rotor bead tracking
    Gore, J
    Bryant, Z
    Stone, MD
    Nöllmann, MN
    Cozzarelli, NR
    Bustamante, C
    [J]. NATURE, 2006, 439 (7072) : 100 - 104
  • [10] Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials
    Graffunder, EM
    Venezia, RA
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 (06) : 999 - 1005